These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Villaseca P Climacteric; 2012 Apr; 15(2):115-24. PubMed ID: 22148909 [TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of nonhormonal drugs on menopausal hot flashes. Li L; Xu L; Wu J; Dong L; Zhao S; Zheng Q Eur J Clin Pharmacol; 2016 Sep; 72(9):1051-8. PubMed ID: 27450233 [TBL] [Abstract][Full Text] [Related]
6. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE. Cobin RH; Goodman NF; Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650 [TBL] [Abstract][Full Text] [Related]
7. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women. Stubbs C; Mattingly L; Crawford SA; Wickersham EA; Brockhaus JL; McCarthy LH J Okla State Med Assoc; 2017 May; 110(5):272-274. PubMed ID: 28649145 [TBL] [Abstract][Full Text] [Related]
8. Managing menopausal symptoms after cancer: an evidence-based approach for primary care. Marino JL; McNamara HC; Hickey M Med J Aust; 2018 Feb; 208(3):127-132. PubMed ID: 29438648 [TBL] [Abstract][Full Text] [Related]
9. Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations. Baber R; Hickey M; Kwik M Drug Saf; 2005; 28(12):1085-100. PubMed ID: 16329712 [TBL] [Abstract][Full Text] [Related]
10. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. Handley AP; Williams M J Am Assoc Nurse Pract; 2015 Jan; 27(1):54-61. PubMed ID: 24944075 [TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for Spine-Related Pain in Older Adults. Fu JL; Perloff MD Drugs Aging; 2022 Jul; 39(7):523-550. PubMed ID: 35754070 [TBL] [Abstract][Full Text] [Related]
12. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Shan D; Zou L; Liu X; Shen Y; Cai Y; Zhang J Am J Obstet Gynecol; 2020 Jun; 222(6):564-579.e12. PubMed ID: 31870736 [TBL] [Abstract][Full Text] [Related]
14. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis. Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122 [TBL] [Abstract][Full Text] [Related]
15. Clinical Inquiry: Which nonhormonal treatments are effective for hot flashes? Kelsberg G; Maragh L; Safranek S J Fam Pract; 2016 May; 65(5):E1-3. PubMed ID: 27275942 [TBL] [Abstract][Full Text] [Related]
16. Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. Thacker HL J Womens Health (Larchmt); 2011 Jul; 20(7):1007-16. PubMed ID: 21675874 [TBL] [Abstract][Full Text] [Related]